BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J, Yoshizawa H. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol. 2011;46:536-544. [PMID: 21132575 DOI: 10.1007/s00535-010-0349-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Tang T, Qiu J, Li G, Huang M, Li Y, Li Y, Gu S. Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients. Clinical Radiology 2018;73:259-65. [DOI: 10.1016/j.crad.2017.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
2 Meguro M, Mizuguchi T, Nishidate T, Okita K, Ishii M, Ota S, Ueki T, Akizuki E, Hirata K. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol 2015; 21(16): 4933-4945 [PMID: 25945007 DOI: 10.3748/wjg.v21.i16.4933] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
3 Sato S, Genda T, Hirano K, Tsuzura H, Narita Y, Kanemitsu Y, Kikuchi T, Iijima K, Wada R, Ichida T. Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma. Liver Int. 2012;32:1382-1390. [PMID: 22681639 DOI: 10.1111/j.1478-3231.2012.02827.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
4 Zhang Z, Zhang Y, Wang Y, Xu L, Xu W. Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma. Onco Targets Ther. 2016;9:123-129. [PMID: 26770061 DOI: 10.2147/ott.s90732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhang Y, Zhang X. Prognostic value of aspartate aminotransferase to platelet ratio index as a noninvasive biomarker in patients with hepatocellular carcinoma: a meta-analysis. Cancer Manag Res 2018;10:3023-32. [PMID: 30214297 DOI: 10.2147/CMAR.S174095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol. 2014;12:1186-1195. [PMID: 24321207 DOI: 10.1016/j.cgh.2013.11.033] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 7.2] [Reference Citation Analysis]
7 Tada T, Toyoda H, Kumada T, Kurisu A, Sugiyama A, Akita T, Ohisa M, Aikata H, Miki D, Chayama K, Tanaka J. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. J Viral Hepat 2021;28:538-47. [PMID: 33215790 DOI: 10.1111/jvh.13444] [Reference Citation Analysis]
8 Zhang Q, Zheng Q, Yu X, He Y, Guo W. Overview of distinct 5-methylcytosine profiles of messenger RNA in human hepatocellular carcinoma and paired adjacent non-tumor tissues. J Transl Med 2020;18:245. [PMID: 32571340 DOI: 10.1186/s12967-020-02417-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
9 Hsieh SY, He JR, Yu MC, Lee WC, Chen TC, Lo SJ, Bera R, Sung CM, Chiu CT. Secreted ERBB3 isoforms are serum markers for early hepatoma in patients with chronic hepatitis and cirrhosis. J Proteome Res 2011;10:4715-24. [PMID: 21877752 DOI: 10.1021/pr200519q] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
10 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. Long-term prognosis of patients with chronic hepatitis C who did not receive interferon-based therapy: causes of death and analysis based on the FIB-4 index. J Gastroenterol 2016;51:380-9. [DOI: 10.1007/s00535-015-1117-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
11 Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y. α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype. J Med Virol. 2014;86:461-472. [PMID: 24166425 DOI: 10.1002/jmv.23824] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
12 Hirosawa T, Morimoto N, Miura K, Ono K, Watanabe S, Fujieda T, Murayama K, Takaoka Y, Nomoto H, Tsukui M, Isoda N, Niki T, Tokushige K, Yamamoto H. The successful treatment of hepatocellular carcinoma arising from congenital hepatic fibrosis using radiofrequency ablation under laparoscopy. Clin J Gastroenterol 2019;12:223-30. [DOI: 10.1007/s12328-018-00932-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Park SJ, Jang JY, Jeong SW, Cho YK, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Park S, Bang HI. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine (Baltimore). 2017;96:e5811. [PMID: 28296720 DOI: 10.1097/md.0000000000005811] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
14 Attallah AM, Omran MM, Attallah AA, Abdallah SO, Farid K, Darwish H, El-Dosoky I, Shaker YM. HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer 2013;109:1657-65. [PMID: 23982602 DOI: 10.1038/bjc.2013.481] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
15 Zweerink S, Mesghenna S, Mueck V, Schulte S, Kuetting F, Quaas A, Goeser T, Nierhoff D. First evaluation of Neighbor of Punc E11 (NOPE) as a novel marker in human hepatocellular carcinoma. Cancer Biomark 2021;30:75-83. [PMID: 32986656 DOI: 10.3233/CBM-190819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K. Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over. World J Hepatol 2020; 12(9): 672-684 [PMID: 33033572 DOI: 10.4254/wjh.v12.i9.672] [Reference Citation Analysis]
17 Zhang X, Svn Z, Liv M, Liu M, Zhang Y, Sun Q. Assessment of Prognostic Value of Aspartate Aminotransferase-to-Platelet Ratio Index in Patients With Hepatocellular Carcinoma: Meta-Analysis of 28 Cohort Studies. Front Med (Lausanne) 2021;8:756210. [PMID: 34901068 DOI: 10.3389/fmed.2021.756210] [Reference Citation Analysis]
18 Xing H, Yan C, Cheng L, Wang N, Dai S, Yuan J, Lu W, Wang Z, Han J, Zheng Y, Yang T. Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma. Tumor Biol 2016;37:15447-56. [DOI: 10.1007/s13277-016-5443-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
19 Campion D, Tucci A, Ponzo P, Caviglia GP. Non-invasive biomarkers for the detection of hepatocellular carcinoma. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.18.02488-6] [Cited by in Crossref: 13] [Article Influence: 4.3] [Reference Citation Analysis]
20 Wei S, Suryani Y, Gowda GA, Skill N, Maluccio M, Raftery D. Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling. Metabolites. 2012;2:701-716. [PMID: 24957758 DOI: 10.3390/metabo2040701] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
21 Cha DI, Jang KM, Kim SH, Kim YK, Kim H, Ahn SH. Preoperative Prediction for Early Recurrence Can Be as Accurate as Postoperative Assessment in Single Hepatocellular Carcinoma Patients. Korean J Radiol 2020;21:402-12. [PMID: 32193888 DOI: 10.3348/kjr.2019.0538] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
22 Toyoda H, Kumada T, Tada T. Highly sensitive Lens culinaris agglutinin-reactive α-fetoprotein: a new tool for the management of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:61-65. [PMID: 22212938 DOI: 10.1159/000333263] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
23 Takada H, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, Yasui Y, Tamaki N, Takaura K, Komiyama Y, Higuchi M, Kubota Y, Wang W, Okada M, Enomoto N, Izumi N. Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma. PLoS One 2018;13:e0198812. [PMID: 29912922 DOI: 10.1371/journal.pone.0198812] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
24 Ito T, Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S. Utility of the FIB-4 Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels. J Viral Hepat. 2015;22:777-783. [PMID: 25608086 DOI: 10.1111/jvh.12389] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
25 Tada T, Toyoda H, Yasuda S, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long‐term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model. Hepatol Res. [DOI: 10.1111/hepr.13512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Huang J, Yang Y, Xia Y, Liu FC, Liu L, Zhu P, Yuan SX, Gu FM, Fu SY, Zhou WP, Liu H, Jiang BG, Pan ZY. Prediction of Patient Survival Following Hepatic Resection in Early-Stage Hepatocellular Carcinoma with Indexed Ratios of Aspartate Aminotransferase to Platelets: A Retrospective Cohort Study. Cancer Manag Res 2021;13:1733-46. [PMID: 33642875 DOI: 10.2147/CMAR.S284950] [Reference Citation Analysis]
27 Wang T, Zhang KH. Progress in research of tumor markers for diagnosis of hepatocellular carcinoma in AFP-negative patients. Shijie Huaren Xiaohua Zazhi 2011; 19(33): 3420-3425 [DOI: 10.11569/wcjd.v19.i33.3420] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Bagheri N, Cinti S, Caratelli V, Massoud R, Saraji M, Moscone D, Arduini F. A 96-well wax printed Prussian Blue paper for the visual determination of cholinesterase activity in human serum. Biosens Bioelectron 2019;134:97-102. [PMID: 30959394 DOI: 10.1016/j.bios.2019.03.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
29 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Niinomi T, Ito T. Oral supplementation with branched-chain amino acid granules prevents hepatocarcinogenesis in patients with hepatitis C-related cirrhosis: A propensity score analysis. Hepatol Res. 2013;Epub ahead of print. [PMID: 23607436 DOI: 10.1111/hepr.12120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
30 Carr BI, Lin CY, Lu SN. Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol 2014;41:415-21. [PMID: 25023358 DOI: 10.1053/j.seminoncol.2014.04.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
31 Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. Liver Cancer. 2015;4:126-136. [PMID: 26020034 DOI: 10.1159/000367735] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 7.7] [Reference Citation Analysis]
32 Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for Hepatocellular Carcinoma. Biomark Cancer. 2017;9:1-9. [PMID: 28469485 DOI: 10.1177/1179299x16684640] [Cited by in Crossref: 61] [Cited by in F6Publishing: 41] [Article Influence: 12.2] [Reference Citation Analysis]
33 Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Natural history of liver-related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model. J Med Virol 2019;91:1837-44. [PMID: 31254403 DOI: 10.1002/jmv.25533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
34 Luo P, Wu S, Yu Y, Ming X, Li S, Zuo X, Tu J. Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage. Pathol Oncol Res. 2020;26:599-603. [PMID: 30661224 DOI: 10.1007/s12253-019-00585-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
35 Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tanaka J, Kagebayashi C, Satomura S. High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol. 2014;49:555-563. [PMID: 24057163 DOI: 10.1007/s00535-013-0883-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
36 Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta. 2013;425:212-220. [PMID: 23954771 DOI: 10.1016/j.cca.2013.08.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]